All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On the 7th March 2017, the European Medicines Agency (EMA) granted marketing authorization to LEDAGA® (chlormethine gel, 160μg/g) to treat Mycosis Fungoides-type Cutaneous T-Cell Lymphoma (MF-CTCL).
The approval of Actelion’s LEDAGA® comes after a positive opinion that was given by the EMA’s Committee for Medicinal Products for Human Use (CHMP) last year, in December 2016. The positive opinion, and the subsequent approval, were based on results of the pivotal 201 study (NCT00168064), previously reported by the Lymphoma Hub.
LEDAGA® has already been approved by the U.S. Food and Drug Administration (FDA) in this indications, and is marketed as VALCHLOR®. A European launch of LEDAGA® is expected to take place after January 2018.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox